We Accept Care Credit Get the care you need, when you need itCareCredit lets you pay for health and wellness services over time with convenient financing options
WADA Prohibition Syn-AKE is not currently listed on the World Anti-Doping Agency (WADA) Prohibited List: Not prohibited for competitive athletes in topical cosmetic applications No known ergogenic or performance-enhancing effects relevant to sport Neuromuscular effects are localized and cosmetic rather than systemic No detection methods or testing protocols established Cosmetic Ingredient Review Status The Cosmetic Ingredient Review (CIR) Expert Panel has not formally evaluated Syn-AKE: No independent CIR safety assessment published as of current date Safety profile based primarily on manufacturer data Anecdotal reports of skin reactions (swelling, redness, itching, stinging) in some users Recommended patch testing before widespread facial application Research Classification: Syn-AKE is available as a cosmetic ingredient for formulation research and topical product development
In a private office setting ( POS 11 ), the practice bills 96372 alongside the corresponding HCPCS Level II J-code to secure separate reimbursement for the drug vial itself
In Canada, advice from the British Columbia Medical Association outlines that 1 mg daily oral CN-Cbl should be used for pernicious anemia or food-bound cobalamin malabsorption (FBCM) whereas in most other cases, a daily dose of 250 g may be used ( In Netherlands, controversy arose when the Dutch Organization of General Practitioners published a 2014 viewpoint that 1 mg daily oral OH-Cbl can be utilised as treatment in cases with a cobalamin count below 148 pmol/L and clinical symptoms, with the Dutch B12 Society disputing the efficacy of this and insisting that the advice from the Dutch Healthcare Institute Pharmacotherapeutic Compass should be followed instead (IM/SC starting dose of 10 injections of 1 mg OH-Cbl at intervals of at least 3 days
